title: Pharmacological strategies for enhancing cognition in schizophrenia.
abstract: Researchers have long recognized that individuals with schizophrenia experience challenges in a wide range of cognitive domains, and research on cognitive impairment in schizophrenia is not a recent phenomena. However, the past 10-20 years have seen an increasing recognition of the central importance of cognition to understanding function and outcome in this illness (Green et al. in Schizophr Bull 26:119-136, 2000), an awareness that has shifted the emphasis of at least some work on schizophrenia. More specifically, there has been a rapidly growing body of work on methods of enhancing cognition in schizophrenia, as a means to potentially facilitate improved outcome and quality of life for individuals with this debilitating illness. The current chapter reviews the results of a range of studies examining adjunctive pharmacological treatments to enhance cognition in schizophrenia using a range of designs, including single-dose studies, open-label repeated dosing studies, and double-blind parallel group and crossover designs with repeated dosing. Although many of the single-dose and open-label studies have suggested positive cognitive effects from a range of agents, few of the larger-scale double-blind studies have generated positive results. The current state of results may reflect the need to identify alternative molecular mechanisms for enhancing cognition in schizophrenia or the need to reconceptualize the ways in which pharmacological agents may improve cognition in this illness, with a concomitant change in the traditional clinical trial study design used in prior studies of cognitive enhancement in schizophrenia.
authors.affiliation: Washington University, St. Louis, One Brookings Drive, Box 1125, St. Louis, MO 63130, USA. dbarch@artsci.wustl.edu
authors.forename: Deanna M
authors.initials: DM
authors.lastname: Barch
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D015259:Dopamine Agents / Q000627:therapeutic use; D018683:Excitatory Amino Acid Agents / Q000627:therapeutic use; D056344:Executive Function / Q000187:drug effects; D018682:GABA Agents / Q000627:therapeutic use; D006801:Humans; D008570:Memory, Short-Term / Q000187:drug effects; D000077408:Modafinil; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D001559:Benzhydryl Compounds; D018678:Cholinergic Agents; D015259:Dopamine Agents; D018683:Excitatory Amino Acid Agents; D018682:GABA Agents; D000077408:Modafinil